Literature DB >> 4816459

Effect of cyclophosphamide on Histoplasma capsulatum infections in mice.

G C Cozad, T J Lindsey.   

Abstract

Mice were injected intraperitoneally (i.p.) with 300 mg of cyclophosphamide (CY)/kg of body weight, and 24 h later were injected i.p. with varying dosages of yeast-phase cells of Histoplasma capsulatum. At specific time intervals organs were removed, ground, and cultured to determine the number of viable organisms contained in the spleen, liver, and lungs. Injection of mice with CY was found to cause a dramatic increase in the numbers of parasites isolated from these organs when compared with non-drug-treated controls. Mice given 10(7) yeast cells showed the largest increase in colony numbers. A greater than fivefold increase in the numbers of organisms isolated from the spleens of CY and 10(3) yeast cell-treated mice, as compared with non-drug-treated animals, was observed at all time periods. The general trend for infected control animals was a decrease in colony numbers. All mice given CY plus 10(7) yeast cells intravenously (i.v.) died by day 20 postinfection. Mice given CY and 10(7) yeast cells i.p. showed no evidence of fatal Histoplasma infection. Deaths occurring by day 5 in CY-treated animals injected with H. capsulatum yeast cells i.v. or i.p. were considered due to bacterial infection or toxicity, or both. Hepatosplenomegaly was observed in mice treated with CY and 10(7) yeast cells of H. capsulatum. Enlarged lungs were also noted. CY control mouse spleens weighed 30% less than normal spleens. Organs of animals injected with H. capsulatum alone did not vary significantly from those of normal mice. Complete drug-induced suppression of humoral antibody response was achieved for 10 days, as determined by hemagglutination titrations.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4816459      PMCID: PMC414796          DOI: 10.1128/iai.9.2.261-265.1974

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  SUPPRESSION OF TISSUE IMMUNITY BY CYCLOPHOSPHAMIDE.

Authors:  M FOX
Journal:  Transplantation       Date:  1964-07       Impact factor: 4.939

2.  STUDIES ON MOUSE ANTIBODIES. I. THE RESPONSE TO SHEEP RED CELLS.

Authors:  F L ADLER
Journal:  J Immunol       Date:  1965-07       Impact factor: 5.422

3.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

4.  The occurrence of opportunistic fungus infections in a cancer hospital.

Authors:  R V HUTER; H S COLLINS
Journal:  Lab Invest       Date:  1962-11       Impact factor: 5.662

5.  Growth of Histoplasma capsulatum in normal, superinfected, and immunized mice.

Authors:  D A ROWLEY; M HUBER
Journal:  J Immunol       Date:  1956-07       Impact factor: 5.422

6.  Effect of histoplasmosis on antibody response to an erythrocyte antigen.

Authors:  G C Cozad; G M Scalarone
Journal:  J Bacteriol       Date:  1969-02       Impact factor: 3.490

7.  Suppression of reticuloendothelial function in the rat with cyclophosphamide.

Authors:  R J Sharbaugh; J B Grogan
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

8.  19S and 17S antibody production in the cyclophosphamide- or methotrexate-treated rat.

Authors:  G W Santos; A H Owens
Journal:  Nature       Date:  1966-02-05       Impact factor: 49.962

9.  Studies on cyclophosphamide-induced tolerance to sheep erythrocytes.

Authors:  A C Aisenberg
Journal:  J Exp Med       Date:  1967-05-01       Impact factor: 14.307

10.  The induction of graft versus host disease in mice treated with cyclophosphamide.

Authors:  A H Owens; G W Santos
Journal:  J Exp Med       Date:  1968-08-01       Impact factor: 14.307

View more
  13 in total

1.  Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice.

Authors:  P Connolly; L J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Host immunological mechanisms in the resistance of mice to leptospiral infections.

Authors:  B Adler; S Faine
Journal:  Infect Immun       Date:  1977-07       Impact factor: 3.441

Review 3.  Host-parasite interaction in fungal infections.

Authors:  N Khardori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

4.  Impairment of granulomatous inflammatory response to Histoplasma capsulatum by inhibitors of angiotensin-converting enzyme.

Authors:  G S Deepe; C L Taylor; L Srivastava; W E Bullock
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

5.  Immunoregulatory responses in experimental disseminated histoplasmosis: lymphoid organ histopathology and serological studies.

Authors:  R P Artz; W E Bullock
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Susceptibility of mice treated with cyclophosphamide to lethal infection with Leptospira interrogans Serovar pomona.

Authors:  B Adler; S Faine
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

7.  Cyclophosphamide pretreatment and protection against malaria.

Authors:  J F Finerty; E P Krehl
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

8.  Effect of cyclophosphamide on experimental Nocardia asteroides infection in mice.

Authors:  B L Beaman; S Maslan
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia.

Authors:  M S Ascher; P B Jahrling; D G Harrington; R A Kishimoto; V G McGann
Journal:  Clin Exp Immunol       Date:  1980-08       Impact factor: 4.330

10.  Pharmacological modulation of suppressor cell activity in mice with disseminated histoplasmosis.

Authors:  G S Deepe; G R Kravitz; W E Bullock
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.